Journey Medical (DERM) Competitors

$7.90 +0.13 (+1.67%)

As of 09/3/2026 04:00 PM Eastern

DERM vs. FBIO, COLL, TBPH, SGP, and ACHV

Should you buy Journey Medical stock or one of its competitors? Journey Medical's main competitors and comparable companies include Fortress Biotech (FBIO), Collegium Pharmaceutical (COLL), Theravance Biopharma (TBPH), Spyglass Pharma (SGP), and Achieve Life Sciences (ACHV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Journey Medical compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Fortress Biotech has a net margin of 163.32% compared to Journey Medical's net margin of -8.95%. Fortress Biotech's return on equity of 83.47% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Journey Medical	-8.95%	-20.23%	-6.60%

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Fortress Biotech currently has a consensus target price of $17.00, suggesting a potential upside of 527.31%. Journey Medical has a consensus target price of $14.00, suggesting a potential upside of 77.22%. Given Fortress Biotech's higher probable upside, equities analysts clearly believe Fortress Biotech is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$68.47M	1.32	$6.82M	$2.64	1.03
Journey Medical	$61.86M	3.60	-$11.43M	-$0.22	N/A

In the previous week, Journey Medical's average media sentiment score of 1.61 beat Fortress Biotech's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Journey Medical	Very Positive

Fortress Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Summary

Fortress Biotech beats Journey Medical on 11 of the 13 factors compared between the two stocks.

How does Journey Medical compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Collegium Pharmaceutical has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	0.99	$62.87M	$1.24	19.11
Journey Medical	$61.86M	3.60	-$11.43M	-$0.22	N/A

Collegium Pharmaceutical presently has a consensus target price of $51.00, suggesting a potential upside of 115.19%. Journey Medical has a consensus target price of $14.00, suggesting a potential upside of 77.22%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Collegium Pharmaceutical is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Collegium Pharmaceutical has a net margin of 5.93% compared to Journey Medical's net margin of -8.95%. Collegium Pharmaceutical's return on equity of 91.43% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Journey Medical	-8.95%	-20.23%	-6.60%

7.3% of Journey Medical shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Journey Medical. MarketBeat recorded 8 mentions for Collegium Pharmaceutical and 0 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.61 beat Collegium Pharmaceutical's score of 0.87 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
Journey Medical	Very Positive

Summary

Collegium Pharmaceutical beats Journey Medical on 12 of the 17 factors compared between the two stocks.

How does Journey Medical compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Theravance Biopharma had 5 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Theravance Biopharma and 0 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.61 beat Theravance Biopharma's score of 1.35 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Positive
Journey Medical	Very Positive

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Theravance Biopharma presently has a consensus price target of $19.40, indicating a potential upside of 13.58%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 77.22%. Given Journey Medical's higher probable upside, analysts clearly believe Journey Medical is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Theravance Biopharma has a net margin of 51.58% compared to Journey Medical's net margin of -8.95%. Theravance Biopharma's return on equity of -0.77% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Journey Medical	-8.95%	-20.23%	-6.60%

Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Theravance Biopharma has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.25	$105.89M	$1.01	16.91
Journey Medical	$61.86M	3.60	-$11.43M	-$0.22	N/A

Summary

Theravance Biopharma beats Journey Medical on 11 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

7.3% of Journey Medical shares are held by institutional investors. 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spyglass Pharma currently has a consensus target price of $44.00, suggesting a potential upside of 51.78%. Journey Medical has a consensus target price of $14.00, suggesting a potential upside of 77.22%. Given Journey Medical's higher probable upside, analysts clearly believe Journey Medical is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Spyglass Pharma has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Journey Medical	-8.95%	-20.23%	-6.60%

Journey Medical has higher revenue and earnings than Spyglass Pharma. Journey Medical is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Journey Medical	$61.86M	3.60	-$11.43M	-$0.22	N/A

In the previous week, Spyglass Pharma had 2 more articles in the media than Journey Medical. MarketBeat recorded 2 mentions for Spyglass Pharma and 0 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.61 beat Spyglass Pharma's score of 0.67 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyglass Pharma	Positive
Journey Medical	Very Positive

Summary

Journey Medical beats Spyglass Pharma on 9 of the 14 factors compared between the two stocks.

How does Journey Medical compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Achieve Life Sciences currently has a consensus target price of $15.00, indicating a potential upside of 80.51%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 77.22%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Journey Medical has higher revenue and earnings than Achieve Life Sciences. Journey Medical is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Journey Medical	$61.86M	3.60	-$11.43M	-$0.22	N/A

Achieve Life Sciences has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Journey Medical	-8.95%	-20.23%	-6.60%

Achieve Life Sciences has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Achieve Life Sciences had 10 more articles in the media than Journey Medical. MarketBeat recorded 10 mentions for Achieve Life Sciences and 0 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.61 beat Achieve Life Sciences' score of 0.97 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Achieve Life Sciences	Positive
Journey Medical	Very Positive

Summary

Achieve Life Sciences beats Journey Medical on 9 of the 16 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DERM vs. The Competition

Export

Metric	Journey Medical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$219.30M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-35.91	787.27	273.29	25.38
Price / Sales	3.60	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	6.93	12.33	12.89	6.14
Net Income	-$11.43M	$2.82B	$3.47B	$349.01M
7 Day Performance	5.76%	2.59%	0.60%	-0.27%
1 Month Performance	22.61%	6.95%	5.73%	0.68%
1 Year Performance	11.90%	9.45%	25.35%	14.84%

Journey Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DERM Journey Medical	1.7793 of 5 stars	$7.90 +1.7%	$14.00 +77.2%	+13.7%	$219.30M	$61.86M	N/A	90	Positive News
FBIO Fortress Biotech	2.4387 of 5 stars	$2.83 -3.4%	$17.00 +500.7%	-8.1%	$97.72M	$68.47M	1.07	170
COLL Collegium Pharmaceutical	2.81 of 5 stars	$27.47 +0.4%	$51.00 +85.7%	-40.1%	$890.40M	$780.57M	22.15	210
TBPH Theravance Biopharma	3.837 of 5 stars	$17.03 +0.1%	$19.40 +13.9%	+24.4%	$883.14M	$107.46M	16.86	110
SGP Spyglass Pharma	2.0397 of 5 stars	$26.60 +1.3%	$44.00 +65.4%	N/A	$877.96M	N/A	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Journey Medical (DERM) Competitors

DERM vs. FBIO, COLL, TBPH, SGP, and ACHV

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to Collegium Pharmaceutical?

Summary

How does Journey Medical compare to Theravance Biopharma?

Summary

How does Journey Medical compare to Spyglass Pharma?

Summary

How does Journey Medical compare to Achieve Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Journey Medical (DERM) Competitors

DERM vs. FBIO, COLL, TBPH, SGP, and ACHV

How does Journey Medical compare to Fortress Biotech?

Is FBIO or DERM more profitable?

Do insiders & institutionals have more ownership in FBIO or DERM?

Do analysts prefer FBIO or DERM?

Which has preferable earnings & valuation, FBIO or DERM?

Does the media refer more to FBIO or DERM?

Which has more risk and volatility, FBIO or DERM?

Summary

How does Journey Medical compare to Collegium Pharmaceutical?

Which has stronger earnings & valuation, COLL or DERM?

Do analysts rate COLL or DERM?

Is COLL or DERM more profitable?

Do institutionals & insiders have more ownership in COLL or DERM?

Which has more volatility and risk, COLL or DERM?

Does the media favor COLL or DERM?

Summary

How does Journey Medical compare to Theravance Biopharma?

Does the media refer more to TBPH or DERM?

Do institutionals & insiders believe in TBPH or DERM?

Do analysts recommend TBPH or DERM?

Is TBPH or DERM more profitable?

Which has more volatility and risk, TBPH or DERM?

Which has preferable valuation & earnings, TBPH or DERM?

Summary

How does Journey Medical compare to Spyglass Pharma?

Do institutionals and insiders hold more shares of SGP or DERM?

Do analysts rate SGP or DERM?

Is SGP or DERM more profitable?

Which has preferable earnings & valuation, SGP or DERM?

Does the media refer more to SGP or DERM?

Summary

How does Journey Medical compare to Achieve Life Sciences?

Do institutionals & insiders believe in ACHV or DERM?

Do analysts recommend ACHV or DERM?

Which has stronger valuation & earnings, ACHV or DERM?

Is ACHV or DERM more profitable?

Which has more volatility and risk, ACHV or DERM?

Does the media favor ACHV or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools